Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.39 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.39 |
| ▸ | FLT1 | P17948 | 3/20 | 0.39 |
| ▸ | FLT4 | P35916 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | PLK4 | O00444 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | PAK4 | O96013 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | CSF1R | P07333 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5994928 | 0.95 | NR4A2 (0.45) | NR4A2IDO1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL1399410 | 0.88 | SLC6A3 (0.49) | NR4A2IDO1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL1399366 | 0.83 | ALDH1A1 (0.55) | NR4A2IDO1SLC6A4MAPTPTGER3 | |
| SCHEMBL1399364 | 0.81 | GFER (0.52) | NR4A2IDO1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL1399315 | 0.76 | IFNAR1 (0.51) | NR4A2IDO1SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4385853 | 0.74 | TAAR1 (0.50) | NR4A2IDO1SLC6A2SLC6A4PTGER3 | |
| SCHEMBL1399340 | 0.72 | IDO1 (0.59) | IDO1SLC6A3SLC6A2SLC6A4GPR84 | |
| SCHEMBL4389000 | 0.72 | IDO1 (0.46) | NR4A2IDO1SLC6A2SLC6A4MAPT | |
| SCHEMBL1399355 | 0.72 | IDO1 (0.47) | IDO1SLC6A3SLC6A2SLC6A4GPR84 | |
| SCHEMBL4397688 | 0.71 | IDO1 (0.46) | NR4A2IDO1SLC6A2SLC6A4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1860100-B1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | LUNDBECK & CO AS H (DK) | 2011-03-02 | — | — | EP | disclosed |
| US-7737170-B2 | Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS | H. LUNDBECK A/S (DK) | 2010-06-15 | — | — | US | disclosed |
| US-7737171-B2 | Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS | H. LUNDBECK A/S (DK) | 2010-06-15 | — | — | US | disclosed |
| US-7652150-B2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIs | H. LUNDBECK A/S (DK) | 2010-01-26 | — | — | US | disclosed |
| US-7563908-B2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2009-07-21 | — | — | US | disclosed |
| US-20080214644-A1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | H. LUNDBECK A/S (DK) | 2008-09-04 | — | — | US | disclosed |
| US-20080214645-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | H. LUNDBECK A/S (DK) | 2008-09-04 | — | — | US | disclosed |
| US-20080176922-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | H. LUNDBECK A/S (DK) | 2008-07-24 | — | — | US | disclosed |
| EP-1701940-B1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | LUNDBECK & CO AS H (DK) | 2008-05-28 | — | — | EP | disclosed |
| EP-1860100-A2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. Lundbeck A/S (DK) | 2007-11-28 | — | — | EP | disclosed |
| US-20060160880-A1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160880-A1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | TPH1, TPH2, HTR2B | NR4A2 2025/4885IDO1 31/4885SLC6A3 25/4885 |
| US-20080176922-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | TPH2, TPH1, HTR1B | NR4A2 3589/4885IDO1 38/4885SLC6A3 26/4885 |
| US-20080214645-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | TPH2, TPH1, HTR1B | NR4A2 3589/4885IDO1 38/4885SLC6A3 26/4885 |
| US-20080214644-A1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | TPH2, TPH1, HTR2B | NR4A2 2111/4885IDO1 49/4885SLC6A3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.